Orthofix Medical (OFIX) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OFIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OFIX, but not buy additional shares or sell existing shares.
View OFIX analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12 month price objectives for Orthofix Medical's stock. Their OFIX share price forecasts range from $16.00 to $16.00. On average, they anticipate the company's stock price to reach $16.00 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts.

Orthofix Medical's stock was trading at $20.53 at the start of the year. Since then, OFIX stock has decreased by 37.4% and is now trading at $12.86.
View the best growth stocks for 2023 here.

Orthofix Medical saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,190,000 shares, an increase of 84.0% from the August 31st total of 646,600 shares. Based on an average daily trading volume, of 385,600 shares, the short-interest ratio is presently 3.1 days.
View Orthofix Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our OFIX earnings forecast.

Orthofix Medical Inc. (NASDAQ:OFIX) posted its quarterly earnings data on Tuesday, August, 8th. The medical device company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.69. The medical device company had revenue of $187.02 million for the quarter, compared to analysts' expectations of $183.80 million. Orthofix Medical had a negative trailing twelve-month return on equity of 1.90% and a negative net margin of 19.74%.

Syntax Stratified SmallCap ETF holds 3,764 shares of OFIX stock, representing 0.39% of its portfolio.

Orthofix Medical updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $752.00 million-$758.00 million, compared to the consensus revenue estimate of $750.57 million.

32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).

Orthofix Medical trades on the NASDAQ under the ticker symbol "OFIX."

Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OFIX stock can currently be purchased for approximately $12.86.

Orthofix Medical (NASDAQ:OFIX) has a market capitalization of $472.46 million and generates $598.45 million in revenue each year. The medical device company earns $-19,750,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis.

The company employs 1,092 workers across the globe.

Orthofix Medical's mailing address is 3451 Plano Parkway, Lewisville TX, 75056. The official website for the company is www.orthofix.com. The medical device company can be reached via phone at (214) 937-2000, via email at markquick@orthofix.com, or via fax at 599 9 461 6978.